You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexbrompheniramine
Accession NumberDB00405  (APRD00770)
TypeSmall Molecule
GroupsApproved
DescriptionDexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.
Structure
Thumb
Synonyms
(+)-Brompheniraminum
(+)-parabromdylamine
(R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine
(S)-(+)-Brompheniramine
(S)-Brompheniramine
3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
D-Brompheniramine
Desbrofeniramina
Dexbromfeniramina
Dexbrompheniramin
Dexbromphéniramine
Dexbrompheniraminum
Parabromodylamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ala-hist Irtablet2 mg/1oralPoly Pharmaceuticals, Inc.2011-08-22Not applicableUs
Pediaventsyrup2 mg/5mLoralCar Win Pharmaceutical Associates, Llc2014-08-04Not applicableUs
Pediaventtablet, chewable1 mg/1oralCar Win Pharmaceutical Associates, Llc2014-08-05Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
DisophrolSchering
DrixoralSchering
Brand mixtures
NameLabellerIngredients
ActiconActipharma, Inc
Ala-hist PEPoly Pharmaceuticals, Inc.
Bionatuss DxpAdvanced Generic Corporation
Chlo HistR. A. Mc Neil Company
Chlo TussR.A. Mc Neil Company
ConexLlorens Pharmaceuticals International Division
Coricidin 'd' Nasal and Sinus CongestionSchering Plough Healthcare Products Canada, A Division Of Schering Canada Inc.
Coricidin D Nasal and Sinus Congestion TabletsSchering Plough Healthcare Products Canada, A Division Of Schering Canada Inc.
DallergyLaser Pharmaceuticals, LLC
Dexbrompherniramine Maleate and Pseudoephedrine Sulfate 6mg/120mgKvk Tech, Inc.
DologenKramer Novis
Dologen 325Kramer Novis
Drixoral Cold & SinusBayer Inc Consumer Care
Drixoral Day/night - Srt/tabsSchering Plough Canada Inc
Drixoral SyrupSchering Plough Canada Inc
Drixtab TabSchering Plough Canada Inc
G-con-XMc Laren Medical
G-dologenKramer Novis
G-P-tuss DxpKramer Novis
M-end DmxR. A. Mc Neil Company
M-end Max DR.A. Mc Neil Company
Panatuss DxpSeyer Pharmatec, Inc.
Panatuss Pediatric Drops DxpSeyer Pharmatec, Inc.
Supress AKramer Novis
Salts
Name/CASStructureProperties
Dexbrompheniramine maleate
ThumbNot applicableDBSALT001411
Categories
UNII75T64B71RP
CAS number132-21-8
WeightAverage: 319.239
Monoisotopic: 318.073161265
Chemical FormulaC16H19BrN2
InChI KeyInChIKey=ZDIGNSYAACHWNL-HNNXBMFYSA-N
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
IUPAC Name
[(3S)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPheniramines
Direct ParentPheniramines
Alternative Parents
Substituents
  • Pheniramine
  • Phenylpropylamine
  • Aralkylamine
  • Halobenzene
  • Bromobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment and relief of symptoms of allergies, hay fever, and colds
PharmacodynamicsIn allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Mechanism of actionDexbrompheniramine competitively binds to the histamine H1-receptor. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Related Articles
AbsorptionAntihistamines are well absorbed from the gastrointestinal tract after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic (cytochrome P-450 system), some renal.

Route of eliminationNot Available
Half life25 hours
ClearanceNot Available
ToxicitySigns of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9648
Blood Brain Barrier+0.9576
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6242
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.93
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.5898
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8398
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.9351
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0758 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9121
hERG inhibition (predictor II)Inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral2 mg/1
Syruporal
Tabletoral
Tablet, extended releaseoral
Tablet (extended-release)oral
Tablet (extended-release); tabletoral
Liquidoral
Syruporal2 mg/5mL
Tablet, chewableoral1 mg/1
Prices
Unit descriptionCostUnit
Ala-hist ir 2 mg tablet0.82USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point113-115US. Patent 3,030,371.
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.63ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.67 m3·mol-1ChemAxon
Polarizability31.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.

General ReferencesNot Available
External Links
ATC CodesR06AB56R06AB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Dexbrompheniramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dexbrompheniramine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dexbrompheniramine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dexbrompheniramine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dexbrompheniramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dexbrompheniramine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dexbrompheniramine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dexbrompheniramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dexbrompheniramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine.
AmoxapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dexbrompheniramine.
AmphetamineAmphetamine may decrease the sedative activities of Dexbrompheniramine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dexbrompheniramine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dexbrompheniramine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dexbrompheniramine.
AzelastineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexbrompheniramine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dexbrompheniramine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dexbrompheniramine.
BenzphetamineBenzphetamine may decrease the sedative activities of Dexbrompheniramine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dexbrompheniramine.
Benzylpenicilloyl PolylysineDexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
BrimonidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dexbrompheniramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dexbrompheniramine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dexbrompheniramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dexbrompheniramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dexbrompheniramine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dexbrompheniramine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dexbrompheniramine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dexbrompheniramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dexbrompheniramine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Dexbrompheniramine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexbrompheniramine.
CitalopramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dexbrompheniramine.
ClidiniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dexbrompheniramine.
ClomipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexbrompheniramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dexbrompheniramine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine.
CyclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.
CyproheptadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine.
DapoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dexbrompheniramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine.
DesipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dexbrompheniramine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Dexbrompheniramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dexbrompheniramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dexbrompheniramine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dexbrompheniramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine.
DifenoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dexbrompheniramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dexbrompheniramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dexbrompheniramine.
DoxepinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
DoxylamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dexbrompheniramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dexbrompheniramine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dexbrompheniramine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dexbrompheniramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dexbrompheniramine.
EfavirenzThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dexbrompheniramine.
EntacaponeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine.
EthanolDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dexbrompheniramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine.
EthosuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dexbrompheniramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dexbrompheniramine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dexbrompheniramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dexbrompheniramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dexbrompheniramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dexbrompheniramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dexbrompheniramine.
EzogabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dexbrompheniramine.
FenfluramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.
FexofenadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dexbrompheniramine.
FlunarizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dexbrompheniramine.
FluoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexbrompheniramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dexbrompheniramine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dexbrompheniramine.
GuanfacineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dexbrompheniramine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dexbrompheniramine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dexbrompheniramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dexbrompheniramine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Dexbrompheniramine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dexbrompheniramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dexbrompheniramine.
LamotrigineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dexbrompheniramine.
LevocabastineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dexbrompheniramine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexbrompheniramine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Dexbrompheniramine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dexbrompheniramine.
LoratadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine.
Lu AA21004The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dexbrompheniramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dexbrompheniramine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dexbrompheniramine.
MephentermineMephentermine may decrease the sedative activities of Dexbrompheniramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dexbrompheniramine.
MethamphetamineMethamphetamine may decrease the sedative activities of Dexbrompheniramine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dexbrompheniramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dexbrompheniramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dexbrompheniramine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dexbrompheniramine.
MethsuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dexbrompheniramine.
MetyrosineDexbrompheniramine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.
MilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
MirtazapineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dexbrompheniramine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dexbrompheniramine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
NabiloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dexbrompheniramine.
NortriptylineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dexbrompheniramine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dexbrompheniramine.
OrphenadrineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexbrompheniramine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dexbrompheniramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dexbrompheniramine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine.
ParaldehydeDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dexbrompheniramine.
ParoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine.
PerampanelThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dexbrompheniramine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dexbrompheniramine.
PhenterminePhentermine may decrease the sedative activities of Dexbrompheniramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dexbrompheniramine.
PipotiazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.
PramipexoleDexbrompheniramine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dexbrompheniramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexbrompheniramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dexbrompheniramine.
PrimidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dexbrompheniramine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.
PromethazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dexbrompheniramine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dexbrompheniramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dexbrompheniramine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.
RamelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dexbrompheniramine.
RopiniroleDexbrompheniramine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine.
RotigotineDexbrompheniramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dexbrompheniramine.
ScopolamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dexbrompheniramine.
SertralineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Dexbrompheniramine.
StiripentolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine.
SuvorexantThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine.
TetrabenazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dexbrompheniramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dexbrompheniramine.
ThalidomideDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dexbrompheniramine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dexbrompheniramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexbrompheniramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexbrompheniramine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.
TiagabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dexbrompheniramine.
TizanidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dexbrompheniramine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine.
TrazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine.
TrimipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexbrompheniramine.
VigabatrinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dexbrompheniramine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine.
ZiconotideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dexbrompheniramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dexbrompheniramine.
ZonisamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dexbrompheniramine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64. [PubMed:9691225 ]
  2. Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053 ]
  3. Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615 ]
  4. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410 ]
  5. Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93. doi: 10.1080/01902140802339623. [PubMed:19085565 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23